D&D bags $137M to fund midphase Alzheimer's, Parkinson's trials

D&D Pharmatech has raised $137.1 million to advance treatments for neurodegenerative diseases and fibrosis. The series B will enable one D&D subsidiary to run phase 2 trials in Alzheimer's and Parkinson’s.